Since the legalization of medical cannabis in 2016, the Australian marijuana industry has been steadily developing — and it’s been attracting attention from international players and investors.
The Investing News Network (INN) has been tracking this growth, and is now ready to bring investors a new website dedicated to helping Australian investors with Australia-focused content.
With cannabis as a core focus, INN Australia will educate investors and connect them with opportunities in this exciting and fast-paced space.
INN’s entry to Australia comes after years of measuring investor sentiment in the country and examining the challenges faced by both investors and companies.
The biggest obstacle for investors in any location is separating the wheat from the chaff, especially in competitive markets like cannabis. Australia is no exception, and INN’s mission has always been to provide high-quality content that investors can use to meet their goals.
The major opportunity in Australian cannabis is also a driver of INN’s move into the sector. Given Australia’s growing population of over 25 million people, as well as its robust agricultural industry, the country is positioned to mold itself into a major force in the international cannabis space.
Australia’s agricultural production is already valued at AU$58 billion and is one of the largest contributors to the nation’s GDP. The country’s agricultural export prowess means that it may be able to harness that strength in the cannabis industry.
What’s more, recreational marijuana has enormous potential in Australia. While cannabis for recreational use is not yet legal in the country, the strides made on the medical side show the trajectory it could take.
Case in point: in 2018, the medical cannabis industry in Australia was valued at just AU$17.7 million, but a forecast from Prohibition Partners, a market consultant agency for the cannabis sector, projects huge growth in value over the next 10 years.
The firm anticipates that by 2028, the medical cannabis market in Australia will hit AU$3.04 billion, while the recreational cannabis market is expected to be valued at AU$7.89 billion in the event that recreational use is legalized.
For investors who get in early, the returns could be massive, and INN Australia’s editorial team will be there for the journey with information on market news and trends, stocks to watch and more.
Readers can expect the following content:
As the Australian cannabis industry develops, INN Australia will be your source for investing success.
Peter Hunt spoke about the path ahead for the nascent industry in the country and how crucial advanced research is for the investment market.
At a cannabis event, an Australian investment banker broke down the current landscape for the cannabis capital markets in the country.
Peak Asset Management hosted an online forum for investors to learn about the opportunity attached to Australia’s psychedelics sector.
Thanks to an updated licence approved by the Office of Drug Control, LGP can now cultivate medical cannabis and make products with the drug.
The health of Elixinol Global in Australia is related to its global performance, particularly in the US market.
Cannvalate has secured the distribution rights for the Rho Phyto product line from Avicanna, a Canadian medical cannabis company.
With three products in its line, Bod now has access to an additional 32 percent of the medical cannabis prescription market in Australia.
Elixinol told investors it is selling Hemp Foods Australia to a Chinese buyer and is halting plans to apply for a medical cannabis cultivation licence for its Nunyara subsidiary.
Canaccord’s Australian Cannabis Index has risen 34 percent over the last month, up from the hit of over 50 percent that it took in 2019.
MPX Australia will be able to cultivate medical cannabis and resin in its unfinished 70,000 square foot cultivation facility in Tasmania.
MGC Pharma will be tasked with providing THC Global with medical cannabis products to be branded under THC Global’s wholly owned subsidiary.
INN takes a look at the growth of CBD stocks on the ASX and some players investors may want to keep their eye on in the sector.
Vir Pharma has signed with Sundial for a three year agreement to receive cannabis oil from the Canadian marijuana company for its oral formulation for chronic pain.
INN takes a look at the current state — and the projected growth — of the cannabis industry in the Oceanic nation for 2020.
Check these companies that sponsor Australia Investing News.
Copyright 2019 All Rights Reserved.
